Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

Christopher M. Coleman, Ye V. Liu, Haiyan Mu, Justin K. Taylor, Michael Massare, David C. Flyer, Gregory M. Glenn, Gale E. Smith, Matthew B. Frieman

Research output: Contribution to journalArticle

Abstract

Development of vaccination strategies for emerging pathogens are particularly challenging because of the sudden nature of their emergence and the long process needed for traditional vaccine development. Therefore, there is a need for development of a rapid method of vaccine development that can respond to emerging pathogens in a short time frame.The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in late 2012 demonstrate the importance of coronaviruses as emerging pathogens. The spike glycoproteins of coronaviruses reside on the surface of the virion and are responsible for virus entry. The spike glycoprotein is the major immunodominant antigen of coronaviruses and has proven to be an excellent target for vaccine designs that seek to block coronavirus entry and promote antibody targeting of infected cells.Vaccination strategies for coronaviruses have involved live attenuated virus, recombinant viruses, non-replicative virus-like particles expressing coronavirus proteins or DNA plasmids expressing coronavirus genes. None of these strategies has progressed to an approved human coronavirus vaccine in the ten years since SARS-CoV emerged. Here we describe a novel method for generating MERS-CoV and SARS-CoV full-length spike nanoparticles, which in combination with adjuvants are able to produce high titer antibodies in mice.

Original languageEnglish (US)
Pages (from-to)3169-3174
Number of pages6
JournalVaccine
Volume32
Issue number26
DOIs
StatePublished - May 30 2014
Externally publishedYes

Fingerprint

Coronavirus Spike Glycoproteins
Coronavirus
Coronavirinae
nanoparticles
Neutralizing Antibodies
neutralizing antibodies
Nanoparticles
mice
proteins
Severe Acute Respiratory Syndrome
Vaccines
vaccine development
viruses
pathogens
glycoproteins
Virion
vaccination
vaccines
Vaccination
antibodies

Keywords

  • Middle East Respiratory Syndrome Coronavirus
  • Neutralizing antibody
  • Severe Acute Respiratory Syndrome Coronavirus
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Coleman, C. M., Liu, Y. V., Mu, H., Taylor, J. K., Massare, M., Flyer, D. C., ... Frieman, M. B. (2014). Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine, 32(26), 3169-3174. https://doi.org/10.1016/j.vaccine.2014.04.016

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. / Coleman, Christopher M.; Liu, Ye V.; Mu, Haiyan; Taylor, Justin K.; Massare, Michael; Flyer, David C.; Glenn, Gregory M.; Smith, Gale E.; Frieman, Matthew B.

In: Vaccine, Vol. 32, No. 26, 30.05.2014, p. 3169-3174.

Research output: Contribution to journalArticle

Coleman, CM, Liu, YV, Mu, H, Taylor, JK, Massare, M, Flyer, DC, Glenn, GM, Smith, GE & Frieman, MB 2014, 'Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice', Vaccine, vol. 32, no. 26, pp. 3169-3174. https://doi.org/10.1016/j.vaccine.2014.04.016
Coleman, Christopher M. ; Liu, Ye V. ; Mu, Haiyan ; Taylor, Justin K. ; Massare, Michael ; Flyer, David C. ; Glenn, Gregory M. ; Smith, Gale E. ; Frieman, Matthew B. / Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. In: Vaccine. 2014 ; Vol. 32, No. 26. pp. 3169-3174.
@article{46d0e08ab70d4ff1bd482339c57039a1,
title = "Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice",
abstract = "Development of vaccination strategies for emerging pathogens are particularly challenging because of the sudden nature of their emergence and the long process needed for traditional vaccine development. Therefore, there is a need for development of a rapid method of vaccine development that can respond to emerging pathogens in a short time frame.The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in late 2012 demonstrate the importance of coronaviruses as emerging pathogens. The spike glycoproteins of coronaviruses reside on the surface of the virion and are responsible for virus entry. The spike glycoprotein is the major immunodominant antigen of coronaviruses and has proven to be an excellent target for vaccine designs that seek to block coronavirus entry and promote antibody targeting of infected cells.Vaccination strategies for coronaviruses have involved live attenuated virus, recombinant viruses, non-replicative virus-like particles expressing coronavirus proteins or DNA plasmids expressing coronavirus genes. None of these strategies has progressed to an approved human coronavirus vaccine in the ten years since SARS-CoV emerged. Here we describe a novel method for generating MERS-CoV and SARS-CoV full-length spike nanoparticles, which in combination with adjuvants are able to produce high titer antibodies in mice.",
keywords = "Middle East Respiratory Syndrome Coronavirus, Neutralizing antibody, Severe Acute Respiratory Syndrome Coronavirus, Vaccine",
author = "Coleman, {Christopher M.} and Liu, {Ye V.} and Haiyan Mu and Taylor, {Justin K.} and Michael Massare and Flyer, {David C.} and Glenn, {Gregory M.} and Smith, {Gale E.} and Frieman, {Matthew B.}",
year = "2014",
month = "5",
day = "30",
doi = "10.1016/j.vaccine.2014.04.016",
language = "English (US)",
volume = "32",
pages = "3169--3174",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "26",

}

TY - JOUR

T1 - Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

AU - Coleman, Christopher M.

AU - Liu, Ye V.

AU - Mu, Haiyan

AU - Taylor, Justin K.

AU - Massare, Michael

AU - Flyer, David C.

AU - Glenn, Gregory M.

AU - Smith, Gale E.

AU - Frieman, Matthew B.

PY - 2014/5/30

Y1 - 2014/5/30

N2 - Development of vaccination strategies for emerging pathogens are particularly challenging because of the sudden nature of their emergence and the long process needed for traditional vaccine development. Therefore, there is a need for development of a rapid method of vaccine development that can respond to emerging pathogens in a short time frame.The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in late 2012 demonstrate the importance of coronaviruses as emerging pathogens. The spike glycoproteins of coronaviruses reside on the surface of the virion and are responsible for virus entry. The spike glycoprotein is the major immunodominant antigen of coronaviruses and has proven to be an excellent target for vaccine designs that seek to block coronavirus entry and promote antibody targeting of infected cells.Vaccination strategies for coronaviruses have involved live attenuated virus, recombinant viruses, non-replicative virus-like particles expressing coronavirus proteins or DNA plasmids expressing coronavirus genes. None of these strategies has progressed to an approved human coronavirus vaccine in the ten years since SARS-CoV emerged. Here we describe a novel method for generating MERS-CoV and SARS-CoV full-length spike nanoparticles, which in combination with adjuvants are able to produce high titer antibodies in mice.

AB - Development of vaccination strategies for emerging pathogens are particularly challenging because of the sudden nature of their emergence and the long process needed for traditional vaccine development. Therefore, there is a need for development of a rapid method of vaccine development that can respond to emerging pathogens in a short time frame.The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in late 2012 demonstrate the importance of coronaviruses as emerging pathogens. The spike glycoproteins of coronaviruses reside on the surface of the virion and are responsible for virus entry. The spike glycoprotein is the major immunodominant antigen of coronaviruses and has proven to be an excellent target for vaccine designs that seek to block coronavirus entry and promote antibody targeting of infected cells.Vaccination strategies for coronaviruses have involved live attenuated virus, recombinant viruses, non-replicative virus-like particles expressing coronavirus proteins or DNA plasmids expressing coronavirus genes. None of these strategies has progressed to an approved human coronavirus vaccine in the ten years since SARS-CoV emerged. Here we describe a novel method for generating MERS-CoV and SARS-CoV full-length spike nanoparticles, which in combination with adjuvants are able to produce high titer antibodies in mice.

KW - Middle East Respiratory Syndrome Coronavirus

KW - Neutralizing antibody

KW - Severe Acute Respiratory Syndrome Coronavirus

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84900416594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900416594&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2014.04.016

DO - 10.1016/j.vaccine.2014.04.016

M3 - Article

VL - 32

SP - 3169

EP - 3174

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 26

ER -